亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

医学 耐受性 脂肪肝 安慰剂 内科学 临床终点 酒精性肝病 胃肠病学 临床试验 不利影响 疾病 肝硬化 病理 替代医学
作者
Rohit Loomba,Erin Morgan,Lynnetta M. Watts,Shuting Xia,Lisa A. Hannan,Richard S. Geary,Brenda F. Baker,Sanjay Bhanot
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:5 (9): 829-838 被引量:93
标识
DOI:10.1016/s2468-1253(20)30186-2
摘要

Background Diacylglycerol-O-acyltransferase 2 (DGAT2) is one of two enzyme isoforms that catalyse the final step in the synthesis of triglycerides. IONIS-DGAT2Rx is an antisense oligonucleotide inhibitor of DGAT2 that is under clinical investigation for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The aim of this trial was to examine the safety, tolerability, and efficacy of IONIS-DGAT2Rx versus placebo in reducing liver fat in patients with type 2 diabetes and NAFLD. Methods This double-blind, randomised, placebo-controlled, phase 2 study consisted of a 2-week screening period, a run-in period of up to 4 weeks, a 13-week treatment period of once-weekly dosing, and a 13-week post-treatment follow-up period. The study was done at 16 clinical research sites in Canada, Poland, and Hungary. Eligible participants were aged 18–75 years, had a body-mass index at screening between 27 kg/m2 and 39 kg/m2, haemoglobin A1c (HbA1c) levels from 7·3% to 9·5%, and liver fat content 10% or greater before randomisation, and agreed to maintain a stable diet and exercise routine throughout the study. Enrolled participants were stratified on the basis of liver fat content during the run-in period (<20% or ≥20%) and then centrally randomised (2:1) to receive once weekly subcutaneous injection of 250 mg IONIS-DGAT2Rx or placebo for 13 weeks. Participants, investigators, funder personnel, and the clinical research organisation staff, including central readers of MRI scans, were all masked to treatment identity. The primary endpoints were the safety, tolerability, and pharmacodynamic effect of IONIS-DGAT2Rx on hepatic steatosis, according to absolute reduction from baseline in liver fat percentage as quantified by MRI-estimated proton density fat fraction and assessed in the per-protocol population. Pharmacodynamic performance was determined in the per-protocol population by the change in liver fat content from baseline to 2 weeks after the last dose. The per-protocol population included all randomised participants who received at least ten doses of study drug, with the first four doses administered in the first 5 weeks, did not miss more than three consecutive weekly doses, and who had no protocol deviations that might affect efficacy. All randomised participants who received at least one dose of study drug were included in the safety analysis. This study is registered with ClinicalTrials.gov, NCT03334214. Findings Between Nov 3, 2017, and Nov 28, 2018, we screened 173 people for eligibility. 44 were enrolled and randomly assigned to receive either IONIS-DGAT2Rx (29 participants) or placebo (15 participants). After 13 weeks of treatment, the mean absolute reduction from baseline was −5·2% (SD 5·4) in the IONIS-DGAT2Rx group compared with −0·6% (6·1) in the placebo group (treatment difference −4·2%, 95% CI −7·8 to −0·5, p=0·026). Reductions in liver fat were not accompanied by hyperlipidaemia, elevations in serum aminotransferases or plasma glucose, changes in bodyweight, or gastrointestinal side-effects compared with placebo. Six serious adverse events occurred in four patients treated with IONIS-DGAT2Rx. No serious adverse events were reported in the placebo group. One of four patients reported three serious adverse events: acute exacerbation of chronic obstructive pulmonary disease, cardiac arrest, and ischaemic cerebral infarction, each considered severe and not related to study drug. Three of four patients reported one serious adverse event of increased blood triglycerides (severe, unrelated to study drug), deep-vein thrombosis (severe, unlikely to be related to study drug), and acute pancreatitis (mild, unrelated to study drug). Interpretation Our results suggest that DGAT2 antisense inhibition could be a safe and efficacious strategy for treatment of NAFLD and support further investigation in patients with biopsy-proven NASH. Based on the pharmacological target, the response to treatment observed in this study population could extend to the broader population of patients with NAFLD. Funding Ionis Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
23秒前
Qiong完成签到,获得积分10
26秒前
墨墨完成签到,获得积分20
29秒前
江添完成签到,获得积分20
30秒前
量子星尘发布了新的文献求助10
36秒前
43秒前
江添发布了新的文献求助10
46秒前
A2QD发布了新的文献求助10
49秒前
神啊救救我吧完成签到,获得积分10
1分钟前
1分钟前
嗯哼哈哈发布了新的文献求助30
1分钟前
在水一方应助林林采纳,获得10
1分钟前
1分钟前
1分钟前
Kennis发布了新的文献求助10
1分钟前
1分钟前
1分钟前
卡他发布了新的文献求助10
2分钟前
林林发布了新的文献求助10
2分钟前
慕青应助卡他采纳,获得10
2分钟前
Kennis完成签到,获得积分10
2分钟前
2分钟前
Esperanza完成签到,获得积分10
2分钟前
2分钟前
量子星尘发布了新的文献求助10
2分钟前
harvey完成签到,获得积分20
2分钟前
harvey发布了新的文献求助10
2分钟前
大个应助借一颗糖采纳,获得10
2分钟前
Lucas应助认真学习采纳,获得10
3分钟前
3分钟前
借一颗糖发布了新的文献求助10
3分钟前
3分钟前
3分钟前
欣一完成签到,获得积分10
3分钟前
林林发布了新的文献求助10
3分钟前
量子星尘发布了新的文献求助20
3分钟前
欣一发布了新的文献求助10
3分钟前
科研通AI6应助科研通管家采纳,获得10
3分钟前
害羞便当完成签到 ,获得积分10
4分钟前
4分钟前
高分求助中
(禁止应助)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Building Quantum Computers 1000
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
Molecular Cloning: A Laboratory Manual (Fourth Edition) 500
Social Epistemology: The Niches for Knowledge and Ignorance 500
优秀运动员运动寿命的人文社会学因素研究 500
Encyclopedia of Mathematical Physics 2nd Edition 420
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4242481
求助须知:如何正确求助?哪些是违规求助? 3775964
关于积分的说明 11856298
捐赠科研通 3430719
什么是DOI,文献DOI怎么找? 1882784
邀请新用户注册赠送积分活动 934828
科研通“疑难数据库(出版商)”最低求助积分说明 841227